663 related articles for article (PubMed ID: 27184586)
21. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
22. Coronary artery bifurcation narrowing treated by Axxess stent implantation: The CARINAX registry.
Briguori C; Donahue M; Visconti G; Focaccio A; Pennacchi M; Lucisano L; Stio R; Mancone M; Calcagno S; Di Palma V; Labalestra N; Signoriello G; Sardella G
Catheter Cardiovasc Interv; 2017 Mar; 89(4):E112-E123. PubMed ID: 27469063
[TBL] [Abstract][Full Text] [Related]
23. Absorb Bioresorbable Vascular Scaffold in Complex Coronary Bifurcation Interventions: Insights From an In Vivo Multimodality Imaging Study.
Bennett J; Vanhaverbeke M; Vanden Driessche N; Adriaenssens T; Hiltrop N; Desmet W; Sinnaeve P; Dubois C
Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512090
[TBL] [Abstract][Full Text] [Related]
24. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S
Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375
[TBL] [Abstract][Full Text] [Related]
25. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
26. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
27. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
[TBL] [Abstract][Full Text] [Related]
28. Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions.
Holck EN; Fox-Maule C; Barkholt TØ; Jakobsen L; Tu S; Maeng M; Dijkstra J; Christiansen EH; Holm NR
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1199-1210. PubMed ID: 31053981
[TBL] [Abstract][Full Text] [Related]
29. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ
Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973
[TBL] [Abstract][Full Text] [Related]
30. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
[TBL] [Abstract][Full Text] [Related]
31. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW
Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346
[TBL] [Abstract][Full Text] [Related]
32. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
[TBL] [Abstract][Full Text] [Related]
33. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
34. Bioresorbable Scaffolds for the Management of Coronary Bifurcation Lesions.
Kawamoto H; Ruparelia N; Tanaka A; Chieffo A; Latib A; Colombo A
JACC Cardiovasc Interv; 2016 May; 9(10):989-1000. PubMed ID: 27198679
[TBL] [Abstract][Full Text] [Related]
35. Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment.
De Paolis M; Felix C; van Ditzhuijzen N; Fam JM; Karanasos A; de Boer S; van Mieghem NM; Daemen J; Costa F; Bergoli LC; Ligthart JM; Regar E; de Jaegere PP; Zijlstra F; van Geuns RJ; Diletti R
Int J Cardiol; 2016 Oct; 221():656-64. PubMed ID: 27423087
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategy.
Kawamoto H; Latib A; Ruparelia N; Miyazaki T; Sticchi A; Naganuma T; Sato K; Figini F; Chieffo A; Carlino M; Montorfano M; Colombo A
Catheter Cardiovasc Interv; 2015 Oct; 86(4):644-52. PubMed ID: 26013748
[TBL] [Abstract][Full Text] [Related]
37. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
[TBL] [Abstract][Full Text] [Related]
38. Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound.
Kawamoto H; Ruparelia N; Latib A; Miyazaki T; Sato K; Tanaka A; Naganuma T; Sticchi A; Chieffo A; Carlino M; Montorfano M; Colombo A
Catheter Cardiovasc Interv; 2017 Apr; 89(5):789-797. PubMed ID: 27545845
[TBL] [Abstract][Full Text] [Related]
39. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
[TBL] [Abstract][Full Text] [Related]
40. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
